Evidence map›Paper›PMID 27761437›Full record

ArticleFrontiers in veterinary science2016

MERS-CoV at the Animal-Human Interface: Inputs on Exposure Pathways from an Expert-Opinion Elicitation.

Anna L Funk, Flavie Luce Goutard, Eve Miguel, Mathieu Bourgarel, Veronique Chevalier, Bernard Faye, J S Malik Peiris, Maria D Van Kerkhove, Francois Louis Roger

Open access · goldAbstract read
In one paragraph

Article in Frontiers in veterinary science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Guideline
  2. Review
  3. MERS-COV in the Middle East, a one health concept approach.One health (Amsterdam, Netherlands) · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Anna L FunkUEME, Institut Pasteur , Paris , France.
Flavie Luce GoutardCirad, UPR AGIRs Research Unit , Montpellier , France.
Eve MiguelCirad, UPR AGIRs Research Unit, Montpellier, France; UMR MIVEGEC, IRD 224-CNRS 5290-UM, Montpellier, France.
Mathieu BourgarelCirad, UPR AGIRs Research Unit , Montpellier , France.
Veronique ChevalierCirad, UPR AGIRs Research Unit , Montpellier , France.
Bernard FayeCirad, UPR AGIRs Research Unit , Montpellier , France.
J S Malik PeirisHKU-Pasteur Research Pole, Hong Kong, China; School of Public Health, University of Hong Kong, Hong Kong, China.
Maria D Van KerkhoveCenter for Global Health, Institut Pasteur , Paris , France.
Francois Louis RogerCirad, UPR AGIRs Research Unit , Montpellier , France.
Centre de Coopération Internationale en Recherche Agronomique pour le Développement · FRInstitut Pasteur · FRInstitut de Recherche pour le Développement · FRUniversity of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nearly 4 years after the first report of the emergence of Middle-East respiratory syndrome Coronavirus (MERS-CoV) and nearly 1800 human cases later, the ecology of MERS-CoV, its epidemiology, and more than risk factors of MERS-CoV transmission between camels are poorly understood. Knowledge about the pathways and mechanisms of transmission from animals to humans is limited; as of yet, transmission risks have not been quantified. Moreover the divergent sanitary situations and exposures to animals among populations in the Arabian Peninsula, where human primary cases appear to dominate, vs. other regions in the Middle East and Africa, with no reported human clinical cases and where the virus has been detected only in dromedaries, represents huge scientific and health challenges. Here, we have used expert-opinion elicitation in order to obtain ideas on relative importance of MERS-CoV risk factors and estimates of transmission risks from various types of contact between humans and dromedaries. Fourteen experts with diverse and extensive experience in MERS-CoV relevant fields were enrolled and completed an online questionnaire that examined pathways based on several scenarios, e.g., camels-camels, camels-human, bats/other species to camels/humans, and the role of diverse biological substances (milk, urine, etc.) and potential fomites. Experts believed that dromedary camels play the largest role in MERS-CoV infection of other dromedaries; however, they also indicated a significant influence of the season (i.e. calving or weaning periods) on transmission risk. All experts thought that MERS-CoV-infected dromedaries and asymptomatic humans play the most important role in infection of humans, with bats and other species presenting a possible, but yet undefined, risk. Direct and indirect contact of humans with dromedary camels were identified as the most risky types of contact, when compared to consumption of various camel products, with estimated "most likely" incidence risks of at least 22 and 13% for direct and indirect contact, respectively. The results of our study are consistent with available, yet very limited, published data regarding the potential pathways of transmission of MERS-CoV at the animal-human interface. These results identify key knowledge gaps and highlight the need for more comprehensive, yet focused research to be conducted to better understand transmission between dromedaries and humans.

Indexed as

animal–human interfaceepidemiologyinfectionMERS-CoVrisk factorstransmission

Identifiers

PMID27761437
PMCPMC5051548
OpenAlexW2526210992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.